Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/ajhp/zxab156 http://scihub22266oqcxt.onion/10.1093/ajhp/zxab156 33821925!ä!33821925 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+J+Health+Syst+Pharm 2021 ; 78 (14): 1277-1281 Nephropedia Template TP {{tp|p=33821925|t=2021. Diffuse alveolar hemorrhage associated with ustekinumab treatment |pdf=|usr=}}{{33821925}} gab.com Text Diffuse alveolar hemorrhage associated with ustekinumab treatment JO: Am J Health Syst Pharm http://www.kidney.de/pget.php?&tw=1&pmid=33821925 #FOAvip PURPOSE: A case of diffuse alveolar hemorrhage (DAH) occurring as a reaction to ustekinumab therapy is reported. SUMMARY: After starting ustekinumab for treatment of psoriatric arthritis, a 46-year-old female presented with flu-like symptoms and cough with blood-tinged sputum that had begun 1 week previously. Her initial computed tomography scan of the chest demonstrated bilateral ground-glass opacities. On bronchoscopy, the bronchoalveolar lavage (BAL) return became bloodier from sample 1 to samples 2 and 3. Her BAL fluid was more than 90% hemosiderin-laden macrophages, a finding consistent with DAH. We ruled out infectious etiologies and other common vasculitis conditions that can cause DAH. A diagnosis of ustekinumab-induced DAH was made due to a temporal relationship between initiation of the drug and the patient's presentation and the absence of infection and other alternate diagnosis. Prior case reports including ustekinumab-induced pneumonitis, interstitial lung disease with a granulomatous component, and lupus syndrome have been reported, with this being the first case of DAH in a patient undergoing treatment of psoriatic arthritis. CONCLUSION: A 46-year-old woman developed DAH during ustekinumab treatment. Symptoms abated after drug discontinuation and supportive treament. Clinicians must remain mindful of this rare complication of ustekinumab use in order to avoid potential delays in appropriate DAH treatment. Twit Text FOAVip Diffuse alveolar hemorrhage associated with ustekinumab treatment ????Am J Health Syst Pharm http://www.kidney.de/pget.php?&tw=1&pmid=33821925 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33821925 #FOAvip English Wikipedia <ref>{{Cite pmid|33821925}}</ref> Diffuse alveolar hemorrhage associated with ustekinumab treatment #MMPMID33821925 Gunasekaran K; Shukla A; Palanisamy N; Singh Rahi M; Wolff A Am J Health Syst Pharm 2021[Jul]; 78 (14): 1277-1281 PMID33821925show ga PURPOSE: A case of diffuse alveolar hemorrhage (DAH) occurring as a reaction to ustekinumab therapy is reported. SUMMARY: After starting ustekinumab for treatment of psoriatric arthritis, a 46-year-old female presented with flu-like symptoms and cough with blood-tinged sputum that had begun 1 week previously. Her initial computed tomography scan of the chest demonstrated bilateral ground-glass opacities. On bronchoscopy, the bronchoalveolar lavage (BAL) return became bloodier from sample 1 to samples 2 and 3. Her BAL fluid was more than 90% hemosiderin-laden macrophages, a finding consistent with DAH. We ruled out infectious etiologies and other common vasculitis conditions that can cause DAH. A diagnosis of ustekinumab-induced DAH was made due to a temporal relationship between initiation of the drug and the patient's presentation and the absence of infection and other alternate diagnosis. Prior case reports including ustekinumab-induced pneumonitis, interstitial lung disease with a granulomatous component, and lupus syndrome have been reported, with this being the first case of DAH in a patient undergoing treatment of psoriatic arthritis. CONCLUSION: A 46-year-old woman developed DAH during ustekinumab treatment. Symptoms abated after drug discontinuation and supportive treament. Clinicians must remain mindful of this rare complication of ustekinumab use in order to avoid potential delays in appropriate DAH treatment. |*Lung Diseases[MESH] |*Ustekinumab/adverse effects[MESH] |Bronchoscopy[MESH] |Cough[MESH] |Female[MESH] |Hemorrhage/chemically induced[MESH] |Humans[MESH]Diffuse alveolar hemorrhage associated with ustekinumab treatment (epmc).pdf DeepDyve Pubget Overpricing